Login to Your Account



FDA won't 'Intercept' OCA in PBC, briefing docs suggest; NASH read-through minimal

By Marie Powers
News Editor

Tuesday, April 5, 2016

Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) gained 13.3 percent Tuesday after briefing documents posted by the FDA ahead of Thursday's meeting of the Gastrointestinal Drugs Advisory Committee suggested a favorable review of the new drug application for obeticholic acid.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription